Dne Pharma AS
Score · fiscal year 2023
86of 100
How to read this: the company is ahead of 96 % of companies in the Morning class Medium in the same sector in 2023. What does this mean?
Rank in the Morning class Medium: 139 of 3,281 · What are Morning company classes?
Place in the whole sector: 966 of 21,088 · Handel
Profile
Lion · Leader
High profitability, high solidity
Position against comparable companies in 2023, not a verdict on the company. Based on profitability 77 and solidity 94 out of 100 among companies in the Morning class Medium in the same sector in 2023. Methodology
Against the sector
Dne Pharma AS is 36 points above the median for companies in the Morning class Medium in the same sector in 2023.
Median score 50 among 3,281 companies.
Against companies in the Morning class Medium in the same sector in 2023: operating margin 16.9% (median 2.9%) and equity ratio 71.3% (median 29.5%).
The numbers behind the score
| Measure | Company | Median |
|---|---|---|
| Operating revenue | 54 MNOK | 91 MNOK |
| Operating margin | 16.9% | 2.9% |
| Profit margin | 15.5% | 2.7% |
| Return on assets | 14.1% | 11.6% |
| Equity ratio | 71.3% | 29.5% |
| Debt-to-equity | 0.40 | 2.32 |
| Current ratio | 2.12 | 1.39 |
| Revenue growth | – | 5.2% |
| Revenue per employee | 10.84 MNOK | 4.75 MNOK |
The median and “ahead of” refer to companies in the Morning class Medium in the same sector in 2023. The bar shows the share of companies the figure is ahead of.
With an index of 86, Dne Pharma AS does better than 96% of companies in the Morning class Medium in the same sector (3,281 companies) in 2023.
Score 2023–2025
- Dne Pharma AS
- Median: companies in the Morning class Medium in the same sector
What the numbers say
Dne Pharma AS had an operating margin of 16.9% and an equity ratio of 71.3% in 2023, and ranks 966 of 21,088 in Handel.
This text is generated automatically from the 2023 accounts.
Three simple methods
The methods give between 59 MNOK and 75 MNOK.
| Method | Multiple | Estimate |
|---|---|---|
| P/E | 10.0 | 66 MNOK |
| EV/EBIT | 8.0 | 75 MNOK |
| P/B | 1.0 | 59 MNOK |
A mechanical estimate from public accounts, not advice. Mechanical estimate from public accounts with fixed multiples. Not a valuation and not advice to buy or sell. The multiples are provisional default values and must be adjusted per sector before the figures are used for anything. See the calculation
Worth a closer look
- positive
Upper quartile on profitability, solidity and liquidity. What sets this company apart from the rest of the sector?
Based on: Operating margin 16.9% (median 2.9%); Equity ratio 71.3% (median 29.5%); Current ratio 2.12 (median 1.39).
Indications based on the latest annual accounts from open data. Not investment or financial advice.
Financial costs were 14.0% of the debt in 2023. The policy rate averaged 3.54 % the same year. This is a plain description of what the debt cost, not a model of interest sensitivity.
See interest rates, prices and exchange rates for the sector
Data quality
No anomalies found in the figures.
Scenario analysis: the sector's weakest year
We have no accounts for 2022, the sector's weakest year, for this company.
The sector's weakest year was 2022, with a median operating margin of 1.5%. Based on the 11 fiscal years we have. The analysis grows as more years are fetched or imported. Methodology
What the score is made of
| Profitability | 77 | weight 30% |
|---|---|---|
| Solidity | 94 | weight 25% |
| Liquidity | 78 | weight 15% |
| Growth | – | no data, left out |
| Consistency | 96 | weight 15% |
Index version 2. Data completeness 85%: the share of the weights that had data.
Questions and answers
How profitable is Dne Pharma AS?
The operating margin was 16.9% in 2023, against a median of 2.9% among companies in the Morning class Medium in the same sector. Return on assets was 14.1%.
How solid is Dne Pharma AS?
The equity ratio was 71.3% in 2023 (median 29.5%). Debt-to-equity was 0.40 (median 2.32).
What is the liquidity of Dne Pharma AS like?
The current ratio was 2.12 in 2023 (median 1.39).
How does Dne Pharma AS compare in Handel?
Dne Pharma AS ranks 966 of 21,088 in Handel for 2023. Among companies in the Morning class Medium it is number 139 of 3,281.
From the Central Coordinating Register
- Org. no.
- 991741208
- Legal form
- AS
- Sector
- Handel (46.460)
- Morning company class
- Medium
- Employees
- 5 registered 10 August 2025
- Founded
- 13 September 2007 19 years in operation
- Share capital
- 0.14 MNOK
- Business address
- Karihaugveien 22, 1086 OSLO
- Municipality
- Oslo rank 63–220 of 357 in Norway
- Latest accounts filed
- 2025
Source: Central Coordinating Register, Brønnøysund Register Centre. The employee count is reported by the company and may be older than the accounts. See the company at the Brønnøysund Register Centre
Ownership and roles
- Chief executive
- Geir Ove Engeset
- Chair of the board
- Esther Elisabeth Paust
- Board member
- Geir Ove Engeset
- Auditor
- Høilund Revisjon AS
Source: Central Coordinating Register, fetched 29 October 2026. Only names are shown.
Owners and shareholdings will appear here once the shareholder data extract is in place.
Coming · not built yet
Error in the data?
Do you see an error in the figures or in how the company is mapped (sector, holding, group)? Let us know. Corrections require documentation.
Figures last fetched 29 October 2026.
Year by year · 2023–2025
| Key figure | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|
| Index | 86 | 71 | 71 | |
| Rank | 966 | 3,061 | 2,948 | |
| Operating margin | 16.9% | 18.1% | 78.0% | |
| Return on assets | 14.1% | 13.9% | 70.3% | |
| Equity ratio | 71.3% | 55.3% | 29.1% | |
| Current ratio | 2.12 | 1.48 | 1.63 | |
| Revenue growth | – | 15.0% | 249.4% |
Accounts
From the Brønnøysund Register Centre, in the company's reporting currency (NOK).
| Key figure | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating revenue | 54.2 MNOK | 62.3 MNOK | 217.8 MNOK |
| Operating profit | 9.2 MNOK | 11.3 MNOK | 169.8 MNOK |
| Profit before tax | 8.4 MNOK | 11.4 MNOK | 174.7 MNOK |
| Net profit | 6.6 MNOK | 8.9 MNOK | 136.2 MNOK |
| Financial expenses | 3.3 MNOK | 2.1 MNOK | 2.8 MNOK |
| Total assets | 83.4 MNOK | 96.5 MNOK | 252.5 MNOK |
| Current assets | 34.4 MNOK | 52.8 MNOK | 234.0 MNOK |
| Equity | 59.5 MNOK | 53.4 MNOK | 73.6 MNOK |
| Retained earnings | 58.0 MNOK | 51.9 MNOK | 72.1 MNOK |
| Total liabilities | 23.9 MNOK | 43.2 MNOK | 178.9 MNOK |
| Current liabilities | 16.2 MNOK | 35.7 MNOK | 143.2 MNOK |
Source: Brønnøysund Register Centre (Register of Company Accounts), fetched 29 October 2026, accounts id 5315385.
Further
Similar companies
- Mediplast AS index 86, rank 950 · compare
- Vega Norge AS index 86, rank 957 · compare
- Vdl Parts Norway AS index 86, rank 960 · compare
- Hexatronic AS index 86, rank 970 · compare
- TP Nordic AS index 86, rank 976 · compare